This Rare Disease Focused Stock Pipeline Is Underappreciated, Analyst Initiating Coverage Says
Cantor Fitzgerald has initiated coverage on KemPharm Inc (NASDAQ:KMPH) with an Overweight rating and a price target of $20. Per the analyst,…
Cantor Fitzgerald Initiates Coverage On KemPharm with Overweight Rating, Announces Price Target of $20
Cantor Fitzgerald analyst Louis Chen initiates coverage on KemPharm (NASDAQ:KMPH) with a Overweight rating and announces Price Target of $20.
KemPharm’s Earnings: A Preview
KemPharm (NASDAQ:KMPH) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement.
Analysts estimate that KemPharm will report an earnings per share (EPS) of $-0.13.
KemPharm’s Lead Prodrug Shows Favorable Safety Profile For Rare Sleeping Disorder
KemPharm Inc (NASDAQ:KMPH) announced topline data from its exploratory Phase 1 trial confirming the relative cardiovascular effects and pharmacokinetics of serdexmethylphenidate…
US Stocks Turn Lower; Nasdaq Drops Over 100 Points
U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Thursday.
Canaccord Genuity Initiates Coverage On KemPharm with Buy Rating, Announces Price Target of $20
Canaccord Genuity analyst Sumant Kulkarni initiates coverage on KemPharm (NASDAQ:KMPH) with a Buy rating and announces Price Target of $20.
Apple To $220? Here Are 5 Other Price Target Changes For Wednesday
Wedbush raised the price target on Apple Inc. (NASDAQ: AAPL) from $200 to $220. However, Wedbush analyst Daniel Ives maintained the stock with an Outperform. Apple shares fell 0.2% to $172.69 in pre-market trading.
Recap: KemPharm Q2 Earnings
KemPharm (NASDAQ:KMPH) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
KemPharm Q2 Adj. EPS $(0.19) Misses $(0.12) Estimate, Sales $1.30M Miss $1.80M Estimate
KemPharm (NASDAQ:KMPH) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.12) by 58.33 percent. This is a 52.5 percent increase over losses of $(0.40) per share from the